July 7, 2015 - iCAD Inc. announced the launch of the iReveal breast density module as the latest addition to the company's PowerLook Advanced Mammography Platform (AMP). The iReveal software is designed to deliver automated, rapid and reproducible assessments of fibroglandular breast density to help identify patients that may experience reduced sensitivity to digital mammography due to dense breast tissue.
An estimated 40 percent of women in the United States have dense fibroglandular breast tissue that may mask the presence of cancerous tissue in standard mammography. In women with dense breasts, mammography sensitivity is reduced to approximately 48 percent from an average of 98 percent. As breast density increases, the risk of developing breast cancer can also increase according to the American Cancer Society. Currently, legislation has been passed in 24 states requiring physicians to report breast density to patients.
iReveal uses an advanced software program to assess breast density based on the range of categories established by the American College of Radiology's Breast Imaging Reporting and Data System (BI-RADS), automating the same analytical approach used by many experienced radiologists. In many cases, patients with dense breast tissue may be recommended for additional screening exams including use of breast tomosynthesis.
iCAD's PowerLook AMP platform is a scalable solution providing facilities with the ability to add a range of options in computer aided detection (CAD), lesion analysis tools, automated breast density assessments, quality assurance and resource planning functionality.
For more information: www.icadmed.com
April 18, 2024 
